Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation

BACKGROUND AND OBJECTIVES: The complement inhibitor eculizumab has dramatically improved the outcome of atypical hemolytic uremic syndrome. However, the optimal duration of eculizumab treatment in atypical hemolytic uremic syndrome remains debated. We report on the French atypical hemolytic uremic s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin J Am Soc Nephrol
Main Authors: Fakhouri, Fadi, Fila, Marc, Provôt, François, Delmas, Yahsou, Barbet, Christelle, Châtelet, Valérie, Rafat, Cédric, Cailliez, Mathilde, Hogan, Julien, Servais, Aude, Karras, Alexandre, Makdassi, Raifah, Louillet, Feriell, Coindre, Jean-Philippe, Rondeau, Eric, Loirat, Chantal, Frémeaux-Bacchi, Véronique
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5220663/
https://ncbi.nlm.nih.gov/pubmed/27799617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06440616
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados